A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is...
Auteurs principaux: | Wilcock, G, Möbius, H, Stöffler, A |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2002
|
Documents similaires
-
Memantine for the treatment of dementia.
par: Wilcock, G
Publié: (2003) -
Memantine for dementia.
par: Mcshane, R, et autres
Publié: (2006) -
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
par: Hanney, M, et autres
Publié: (2012) -
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
par: Majed Al-Jeraisy, et autres
Publié: (2021-04-01) -
A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
par: Kieburtz, K, et autres
Publié: (2013)